Time-of-Day Specified Ipilimumab and Nivolumab for the Treatment of Stage IV Unresectable Melanoma, The TIME Trial
Launched by EMORY UNIVERSITY ·
Trial Information
Current as of November 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether the time of day when two cancer-fighting drugs, ipilimumab and nivolumab, are given can affect how well they work for people with advanced melanoma, a serious type of skin cancer that has spread or cannot be removed by surgery. These drugs help the body’s immune system attack the cancer, but they don’t work for everyone. Researchers want to find out if giving the treatment in the morning instead of later in the day can improve patients’ chances of responding to the therapy and living longer.
The trial is for adults aged 65 to 74 who have stage IV melanoma or melanoma that can’t be removed by surgery. If you join, you will receive treatment with ipilimumab and nivolumab, and the doctors will carefully watch how your cancer responds depending on what time of day you get the medicine. This study is not yet open for enrollment, but it hopes to find better ways to improve treatment for people with advanced melanoma by considering something as simple as the timing of medication.
Gender
ALL
Eligibility criteria
About Emory University
Emory University, a leading research institution located in Atlanta, Georgia, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Emory harnesses the expertise of its renowned faculty and state-of-the-art facilities to conduct cutting-edge research across various fields, including oncology, neurology, and infectious diseases. The university's commitment to ethical research practices and patient safety ensures that all clinical trials are designed to generate valuable data that can lead to significant therapeutic advancements. By fostering partnerships with local hospitals and community organizations, Emory strives to translate research findings into real-world applications, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Michael Lowe, MD, MA
Principal Investigator
Emory University Hospital/Winship Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported